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NeuraminidaseTay–Sachs disease is a severe lysosomal storage disorder caused bymutations in the HEXAgene coding forα sub-
unit of lysosomal β-Hexosaminidase A enzyme, which converts GM2 to GM3 ganglioside. HexA−/−mice, depleted
of the β-Hexosaminidase A iso-enzyme, remain asymptomatic up to 1 year of age because of a metabolic bypass
by neuraminidase(s). These enzymes remove a sialic acid residue converting GM2 toGA2, which is further degrad-
ed by the still intact β-Hexosaminidase B iso-enzyme into lactosylceramide. A previously identified ganglioside
metabolizing neuraminidase, Neu4, is abundantly expressed in the mouse brain and has activity against gangli-
osides like GM2 in vitro. Neu4−/−mice showed increased GD1a and decreased GM1 ganglioside in the brain sug-
gesting the importance of the Neu4 in ganglioside catabolism. Mice with targeted disruption of both HexA and
Neu4 genes showed accumulating GM2 ganglioside and epileptic seizures with 40% penetrance, indicating that
the neuraminidase Neu4 is a modulatory gene, but may not be the only neuraminidase contributing to the met-
abolic bypass in HexA−/−mice. Therefore, we elucidated the biological role of neuraminidase-1 in ganglioside
degradation in mouse. Analysis of HexA−/−Neu1−/− and HexA−/−Neu4−/−Neu1−/−mice models showed sig-
nificant contribution of neuraminidase-1 on B-series ganglioside degradation in the brain. Therefore, we specu-
late that other neuraminidase/neuraminidases such as Neu2 and/or Neu3 might be also involved in the
ganglioside degradation pathway in HexA−/−mice.
© 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).1. Introduction
Tay–Sachs disease is the second common lysosomal storage disorder
caused by mutations in the HEXA gene [1]. The HEXA gene encodes the
α-subunit of the lysosomal β-Hexosaminidase A (HexA) [E.C3.2.1.52]
enzyme which removes N-acetyl-galactosamine residues from the
GM2 ganglioside converting it to the GM3 ganglioside for further degra-
dation. Tay–Sachs patients suffer from progressive neuronal degenera-
tion, muscle weakness, blindness and epilepsy and affected with the
severe infantile form, they die in the second to the fourth year of their
life [2]. The β-Hexosaminidase A deficient mouse model of Tay–Sachs
disease (HexA−/−) does notmimic the human disease because the gan-
glioside degradation pathway differs between mice and humans [3,4,5,
6,7]. The behaviors and the motor coordination of these mice were the
same as the wild type mice (HexA+/+) until at least 1 year of life
span. Only a limited accumulation of GM2 ganglioside and the membra-
nous cytoplasmic bodies were observed in the brain of HexA−/−mice.
This inequality revealed that there may be a bypass in the GM2antepe).
. This is an open access article underganglioside degradation. Instead of going through the GM3 pathway,
GM2 ganglioside may be degraded via the glycolipid GA2 (asialo-form
of GM2 ganglioside), which bypasses the GM3 dependent degradation
[3]. It has been proposed that the activities of neuraminidase(s) [E.-
C.3.2.1.18], which remove the sialic acid residue from the GM2 ganglio-
side converting it to the GA2 ganglioside that is further degraded by β-
Hexosaminidase B enzyme to lactosylceramide, take part in the
bypassing pathway of the GM2 ganglioside degradation [5,7]. A
previously identified ganglioside metabolizing neuraminidase-4 is
abundantly expressed in the mouse brain and has activity against gan-
gliosides like GM2, in vitro. In the mouse model with the neuraminidase
Neu4 deficiency, lysosomal storage was shown in the lung and the
spleen with microscopic investigation. In addition, abnormal ganglio-
side patterns (increased GD1a and decreased GM1 levels) in the brain
of mice were shown by thin layer chromatography analysis [8]. To elu-
cidate whether neuraminidase Neu4 is involved in the GM2 ganglioside
degradation in vivo, a mouse model with combined deficiencies of β-
Hexosaminidase A and neuraminidase-4 (HexA−/−Neu4−/−) was gen-
erated. Double knockout mice have multiple degenerating neurons in
the cortex and hippocampus and multiple layers of cortical neurons ac-
cumulate GM2 ganglioside. The significantly higher level of the GM2the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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Neu4−/− mice. More importantly mice with the HexA and Neu4 en-
zyme deficiency had epileptic seizures (the hallmark of Tay–Sachs
patients), which were not observed in mice with a single HexA enzyme
deficiency. Since only 40% of all mice with the double enzyme deficiency
had seizures, we postulated that the Neu4 is a modulatory gene and
neuraminidase Neu4 is not the only neuraminidase contributing to the
metabolic bypass seen in the HexA deficient mice [9]. Therefore, we
suggested that another neuraminidase and/or neuraminidases such as
lysosomal neuraminidase Neu1 might have a role in metabolic bypass.
In this study we generated and analyzed the mice models with deficien-
cies of three enzymes; β-Hexosaminidase A, neuraminidase-1 and
neuraminidase-4, to investigate the contribution of neuraminidase(s) on
the ganglioside degradation in mice.2. Material and methods
2.1. Animals
Triple mice with three enzyme deficiencies (HexA−/−Neu4−/−-
Neu1−/−) were previously generated by Prof. Dr. Volkan Seyrantepe
inMontreal, Canada and donated by Prof. Alexey V. Pshezhetsky (Centre
Hospitaliere Universitaire Sainte-Justine, University of Montreal,
Montreal, Quebec, Canada). These mice were generated by breeding
double knockout mice with the deficiency of β-Hexosaminidase A and
neuraminidase-4 (HexA−/−Neu4−/−) with hypomorphic mouse model
(CathAS190A-Neomice was named as Neu1−/−mice in this study) with re-
duced neuraminidase-1 activity [10]. Later on, triple mice were breed
with wild type mice strain C57/Black6 to further obtain single
(Neu4−/−, HexA−/−, Neu1−/−) and double deficient (HexA−/−Neu4−/−
and HexA−/−Neu1−/−) mice as well as triple deficient mice in the same
genetic background. All mice were bred and maintained in the Turkish
Council onAnimal Care (TCAC) accredited animal facility of Izmir Institute
of Technology according to the TCAC guidelines. Micewere housed under
constant temperature and humidity on a 12 h light:dark cycle. The animal
care and the use in the experimentswere granted by the Animal Care and
Use Committee of Ege University, Izmir, Turkey.2.2. Genotyping
All mice were genotyped by PCR for three alleles from the genomic
DNA extracted from mice's tail. The PCR for Neu4 and HexA alleles [9]
and Neu1 [10] was performed as previously described.2.3. Lipid isolation and ganglioside purification
Age matched single, double and triple deficient mice as well as con-
trol mice (3, 6 and 9months old) were sacrificed by cervical dislocation.
100 mg brain tissue from their right and left cerebral hemispheres was
removed, immediately frozen on dry ice and kept at−80 °C until need-
ed. To isolate total lipids and purify ganglioside from brain tissue an op-
timized form of Folch lipid extraction method was used as previously
described [9,11].2.4. Thin layer chromatography and orcinol staining
Isolated gangliosides were run according to a previous method [9].
Orcinol (Sigma-447420) dye was dissolved with 25% sulfuric acid in
glass TLC sprayer (Sigma). The dye was sprayed on the plates and incu-
bated at 120 °C for 10min. The gangliosides were identified by compar-
ing them with the brain ganglioside standards (Avanti Polar Lipids).
Images of plates were taken with the VersaDoc™ Imaging System for
quantification.2.5. Mass spectrometric analysis of gangliosides
For mass spectrometric analysis, lipids were extracted by a different
procedure. 3 ml of methanol was added to 300 mg brain tissue and ho-
mogenized in a glass vial with a Heidolph Silent Crusher M Politron Ho-
mogenizer. 3 ml of chloroform was added to the suspension and the
mixture was incubated at 37 °C in an ultra sound bath by turning on
the ultra sound 3 times for 3 min within the 15 min incubation period.
Samples were centrifuged at 2000 rpm at RT and the supernatant was
taken in a new glass vial. Extraction of the tissue pellet was repeated
once with 2 ml chloroform:methanol:water (10:10:1) and once with
chloroform:methanol:water (30:60:8). Supernatants were combined
and evaporated with N2. Lipid samples were used by Prof. Roger
Sandhoff's laboratory (German Cancer Research Center) for mass spec-
trometric analysis.
2.6. Mass spectrometric analysis of lipids
Lipids were extracted from samples as mentioned above. Synthetic
lipid standards were purchased from Avanti Polar Lipids. Chemicals
and solvents were purchased from Sigma-Aldrich. All standards and
lipid extracts were dissolved in an appropriate volume of 5 mM ammo-
nium formate in methanol–chloroform 5:1 (v/v) just prior to analysis.
Mass spectrometric analyses were conducted on a hybrid triple quadru-
pole/linear ion trap 4000 QTRAP instrument (Applied Biosystems/MDS
Sciex, Ontario, Canada) which is equipped with an electrospray ioniza-
tion source. Lipid solutions were infused into the electrospray source
at a 15 μl/min flow rate. The instrument was used either in the single-
stage MS mode or in the tandem MS mode (product ion or precursor
ion). The spray was operated for the detection of positive mode ions
264.4 for ceramide species [12] and 184.4 for phosphatidylcholine and
sphingomyelin species [13]. The Precursor scan studies were operated
using the following 4000 QTRAP instrumental parameters: curtain gas
(CUR), 10.00 arbitrary units (arb); ion spray voltage (IS), 3500.00; tem-
perature (TEM), 0.00 °C; ion source gas 1 (GS1), 10.00; ion source gas 2
(GS2), 0.00; collision gas (CAD), 6.00 arb; collision energy (CE), 52 eV;
Collision Cell Exit Potential (Cxp), 9; Declustering potential (DP), 60 V;
Entrance potential, 10. For each spectrum were collected as a sum of
the 20 multichannel analysis (MCA) scans during 3.350 min time
period.
2.7. Immunohistochemical analysis
For immunohistochemical analysis, mice were anesthetized and
transcardiac perfusion was initiated with phosphate-buffered saline
(PBS) followed by 4% paraformaldehyde in PBS. Brain tissues were re-
moved and placed in the same fixative overnight at 4 °C, and then treat-
ed sequentially with 10%, 20% and 30% sucrose in PBS overnight at 4 °C.
Brains were embedded in OCT (Sakura) and kept at−80 °C until used.
Ten micrometer sections were taken by Leica Cryostat (CM1850-UV) at
−20 °C and the GM2 ganglioside was immunostained as previously de-
scribed by KM966 primer and DyLight 488 secondary antibody (Ther-
mo) [9]. Slides were studied on fluorescent Microscopy (Olympus
BX53).
2.8. Expression analysis
Expression analysis of neuraminidases (Neu1, Neu2, Neu3 and
Neu4) [14] and HexB in 3 and 6 month old HexA−/−, Neu4−/−,
HexA−/−Neu4−/−, HexA−/−Neu4−/−Neu1−/− as well as wild type
mice was done with the Roche LightCycler 480 system using Roche
LightCycler 480 SYBR Green I Master Mix after RNA was extracted
from 100 mg brain tissue by TRIzol Reagent (Invitrogen) and then
cDNA was synthesized by NEB Protoscript M-MuLvTaq RT PCR kit.
GAPDH gene was used as internal control, 3 mice were analyzed from
each group and all samples were run in duplicate. 40 ng of cDNA was
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Roche LightCycler 480 SYBR Green I Master Mix. Conditions for PCR
were; 1 cycle 10 min at 95 °C; 45 cycles 20 s at 95 °C, 15 s at 61 °C,
22 s at 72 °C, reading was done after each cycle. In the end 1 cycle
30 s at 95 °C, 10 s at 60 °C then continuous reading was applied while
temperature increases to 99 °C to detect primer dimer if exists. The fol-
lowing pairs of primers were used for expression analysis; Neu1F: 5′-
TCATCGCCATGAGGAGGTCCA, Neu1R:5′-AAAGG GAATGCCGCTCACT
CCA, Neu2F: 5′-CGCAGAGTTGATTGTCCTGA, Neu2R: 5′-TTCTGA GCAG
GGTGCAGTTTCC, Neu3F: 5′-CTCAGTCAGAGATGAGGATGCT, Neu3R: 5′-
GTGAGACATA GTAGGCATAGGC, Neu4F: 5′-AGGAGAACGGTGCTCTTC
CAGA, Neu4R: 5′-GTTCTTGCCAG TGGCGATTTGC, HexBF: 5′-AGTGCG
AGTCCTTCCCTAGT, HexBR: 5′-ATCCGGACATCGTTTGGTGT, GADPHF:
5′-CCCCTCATTGACCTCAACTAC, GADPHR: 5′-ATGCATTGCTGACAATCT
TGAG.
2.9. Enzyme assays
Neuraminidase (Sigma 69587), β-glucosidase (SIGMA M3633), β-
galactosidase (SIGMA M1633) and α-L-iduronidase (SC220961) en-
zyme activities in the brain were assayed by using the corresponding
fluorogenic 4-methylumbelliferyl substrates as previously described
[15]. 50 mg brain tissue from 6 month old WT, HexA−/−, Neu4−/−,
HexA−/−Neu4−/− and HexA−/−Neu4−/−Neu1−/−mice was homoge-
nized in 0.4 M sodium acetate (pH 4.3) buffer by a mini homogenizer
and sonicated at 60 V for 10 s. 10 μl of homogenate was incubated in a
sodium acetate buffer that has 0.5 mM substrate; reaction was stopped
with 0.2 M glycine buffer (pH 10.8) after 0.5 h of incubation at 37 °C.
Samples were read via a spectrofluorometer at excitation wavelength
of 365 nm and emission wavelength of 445 nm. Protein concentration
in the sample was measured by Bradford reagent (Sigma) and specific
enzyme activity was calculated.
3. Results
3.1. Generation of single, double and triple deficient mice
Previously generated HexA−/−Neu4−/−Neu1−/− male mice were
crossed with C57/Black6 female mice. Mice were genotyped for 3Fig. 1. Thin layer chromatography and orcinol staining for gangliosides of 3 month (A) and 6m
deficient counterparts.different genes (HexA, Neu4 and Neu1) by PCR method as previously
described [9,16]. Mice with desired genotypes were crossed with each
other to get single (HexA−/−, Neu4−/−, and Neu1−/−), double
(HexA−/−Neu4−/− and HexA−/−Neu1−/−) and triple deficient
(HexA−/−Neu4−/−Neu1−/−) mice in the same genetic background.
Mated mice heterozygotes for 3 genes gave offspring at the expected
Mendelian ratio (1:2:1) and generated triple deficient mice were
healthy and lived longer than 2 years. There were no significant differ-
ences in weight gain between mutant and littermate control mice.
Both males and female triple deficient mice were fertile.
3.2. Altered ganglioside levels in both HexA−/−Neu1−/− and HexA−/
−Neu4−/−Neu1−/−mice
Thin layer chromatography analysis of the brain gangliosides
showed that 3 month old single HexA−/− and double HexA−/−-
Neu1−/−mice had an increased level of GM2 ganglioside in comparison
towild typemice (Fig. 1). InHexA−/−mice, the accumulation of theGM2
ganglioside was previously shown [3,4,5]. Although we determined a
slightly increased level of GD1 ganglioside (~1.3 fold) in HexA−/−-
Neu1−/− mice in comparison to HexA−/− mice, the levels of GM1 and
GM2 in the gangliosideswere not different in thesemice's brain. To com-
pare the effect of age on accumulation, 6 month old mice's brain gangli-
osides were also analyzed. We found that the GM2 ganglioside level in
the 6 month old mice's brain was not significantly different than that
of the 3 month old mice (Fig. 1). However, in the detailed analysis of
6 month old mice's brain gangliosides with mass spectrometry, we
showed that HexA−/−Neu1−/−mice have a significant increased level
of GD2 ganglioside (~3 fold) and GD1 ganglioside (~1.3 fold), and a rela-
tively decreased level of GD3 ganglioside (~0.8 fold), in comparison to
HexA−/−mice whereas GM1, GM2, GM3, and GT1 gangliosides and SM4
sulfatide levels remained similar to HexA−/− mice (Fig. 4A). Besides
the similarities in the levels of GM1 and GM2 gangliosides in both mice,
there was a relative decrease in the ratio of GM2/GM1 gangliosides in
HexA−/−Neu1−/−mice than that of HexA−/−mice (Fig. 4B).
Neuraminidase-4 deficiency in three different mice (Neu4−/−,
HexA−/−Neu4−/− or HexA−/−Neu4−/−Neu1−/−) caused a decreased
level of GM1 ganglioside that could be determined by both thin layer
chromatography (Fig. 2) and mass spectrometric (Fig. 4) analysis, inonth (B) HexA+Neu1 double deficient mice with its wild type and single HexA and Neu1
Fig. 2. Thin layer chromatography and orcinol staining for gangliosides of 3 month (A), 6 month (B) and 9month (C) old triple deficient (HexA+Neu4+Neu1) mice with its wild type,
single HexA and Neu4 deficient and double HexA + Neu4 deficient counterpart.
75Z.K. Timur et al. / Molecular Genetics and Metabolism Reports 4 (2015) 72–82comparison to wild type and age-matched HexA−/−mice as previously
shown due to the lack of the activity of the neuraminidase-4 on gangli-
oside GD1a [8]. Although HexA−/−Neu4−/− mice showed ~2 fold in-
crease in the level of the GM2 ganglioside compared to wild type and
HexA−/− mice in all 3, 6 and 9 month old age groups, as previously
shown [9], HexA−/−Neu4−/−Neu1−/−mice showed very similar GM2
ganglioside level in comparison to HexA−/−Neu4−/− mice both in
thin layer chromatography (Fig. 2 and Fig. 3) and mass spectrometric
analysis (Fig. 4). Accumulation level of the GM2 ganglioside is indicated
by the ratio of GM2/GM1 ganglioside. While in the HexA−/− mice the
GM2/GM1 ratio is almost ~1.3 fold, and this ratio increases above ~2
fold in HexA−/−Neu4−/− mice. We determined that HexA−/−-
Neu4−/−Neu1−/−mice had a higher GM2/GM1 ratio than the HexA−/−
mice but lower ratio than HexA−/−Neu4−/− mice which could beFig. 3. (A) Relative GM1, GM2, GM3, GD1a, GD1b, and GT1b levels and (B) GM2/GM1 ratio of 6 mon
HexA + Neu4 and HexA + Neu1 deficient mice brain analyzed with thin layer chromatographrelated to the slightly increased level of GM1 ganglioside by the deficien-
cy of the neuraminidase-1 (Fig. 4A and B).
Although the levels of GM2 ganglioside in brain were similar in
3 month and 6 month old HexA−/−Neu4−/− and HexA−/− -
Neu4−/−Neu1−/− mice, mass spectrometry analysis revealed that
HexA−/−Neu4−/−Neu1−/−mice had an altered ganglioside profile
in general content. The HexA−/−Neu4−/−Neu1−/− mice with
lack of β-Hexosaminidase and neuraminidase-4 and reduced
neuraminidase-1 activity (10% activity) showed significant increased
level of GM3 ganglioside (~1.5 fold), GD1 ganglioside (~1.2 fold), GD2 gan-
glioside (~4 fold), GT1 ganglioside (~1.6 fold), GD3 ganglioside (~1.2 fold)
and the glycolipid sulfatide (SM4s) (~1.2 fold) than that of HexA−/−mice
(Fig. 4). These findings on the ganglioside level changes indicate the pos-
sible role of neuraminidase-1 and neuraminidase-4 on the gangliosideth old HexA+ Neu4+ Neu1 mice with wild type, single HexA and Neu4 deficient, double
y (n = 3, *p b 0.05, **p b 0,01).
Fig. 4. (A) Relative GM1, GM2, GM3, GD1, GD2, GD3, GT1 and SM4 levels and (B) GM2/GM1 ratio of 6 month old HexA+ Neu4 + Neu1 mice with wild type, single HexA and Neu4 deficient,
double HexA + Neu4 and HexA + Neu1 deficient mice brain analyzed with mass spectrometry (n = 3; ns = not significant; *p b 0.05; **p b 0.01; ***p b 0.001).
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neuraminidase-1 activity especially on b-series ganglioside catabolism
since reduced activity results in higher amount of GD1, GD2, GD3 and GT1
gangliosides.3.3. Altered secondary lipid composition in both HexA−/−Neu4−/− and
HexA−/−Neu4−/−Neu1−/−mice
Effects of β-Hexosaminidase and neuraminidase(s) deficiency on the
secondary lipid composition in brain tissue were also studied. Whole
brain tissue from 9 month old Wt, HexA−/−, HexA−/−Neu1−/−,
HexA−/−Neu4−/−, and HexA−/−Neu4−/−Neu1−/−mice and their con-
trol groups was analyzed with mass spectrometry. Phosphatidylcholine
(PC) and sphingomyelin (SPM) species were monitored by parent ion
scanning of m/z 184.4 in positive ion mode. Ceramide (Cer), and cer-
amide species such as ceramide phosphate (CerP), galactosylceramide
(GalCer) and lactosylceramide (LacCer) were analyzed by parent ion
scanning of m/z 264.4 in positive ion mode. Both β-Hexosaminidase A
and neuraminidase-4 deficiency caused a decrease in level of CerP,
GalCer and LacCer in brain tissue compared toWTmice. We also deter-
mined ~1.06 fold increase in the ceramide level in the Neu4−/− mice
(data not shown). All of the ceramide species levels were slightly
lower in both HexA−/−Neu4−/− and HexA−/−Neu4−/−Neu1−/−
mice compared to WTmice, whereas HexA−/−Neu4−/−Neu1−/− defi-
cient mice had elevated amount of ceramide content compared to
HexA−/−Neu4−/− mice and Wt mice which indicates the possiblerole of neuraminidase-1 in the ganglioside degradation pathway (Fig.
5A).
Mass spectrometry analysis of SPM and PC species in the 9 month
old mice brains revealed that HexA−/−Neu4−/− mice had ~1.2 and
~1.11 fold increase in SPM and PC content compared to WT mice. Sim-
ilarly there was ~1.16 and ~1.05 fold increase in SPM and PC amount in
HexA−/−Neu4−/−Neu1−/− mice brain compared to WT mice brain.
These results may also indicate the possible role of neuraminidase-1
in the SPM and PC metabolism. Deficiency of neuraminidase-1 in
addition to β-Hexosaminidase A and neuraminidase-4 leads to an
increase in the SPM but a decrease in the PC level in the mouse brain
(Fig. 5B).3.4. Increased GM2 ganglioside accumulation in the brain cortex of HexA
−/−,
HexA−/−Neu4−/−, HexA−/−Neu4−/−Neu1−/−mice
Accumulation of the GM2 ganglioside in the coronal sections of the
brain was also studied by immunohistochemistry analysis using the
human–mouse chimeric monoclonal antibody, KM966 [9]. No GM2 gan-
glioside accumulation was detected in the brain of wild type or
Neu4−/−mice from 3 months (Fig. 6), 6 months (Fig. 7) and 9 months
(Fig. 8). However in the hippocampus of HexA−/−, HexA−/−Neu4−/−
and HexA−/−Neu4−/−Neu1−/−mice, relatively high level of GM2 accu-
mulationwas detected compared to the cortex. GM2 ganglioside specific
immunostaining of the brain revealed that although HexA−/−Neu4−/−
mice and HexA−/−Neu4−/−Neu1−/− mice had higher amount of
Fig. 5. (A) Relative and (B) fold changes of ceramide (Cer), ceramide phosphate (CerP), galactosylceramide (GalCer), lactosylceramide (LacCer), sphingomyelin (SPM) and phosphatidyl-
choline (PC) levels of 9 month old HexA + Neu4 + Neu1 mice with wild type, single HexA deficient, double HexA + Neu4 and HexA + Neu1 deficient mice brain analyzed with mass
spectrometry (n = 3; p b 0.005).
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mulation were similar in the brains of different deficient mice.
3.5. Altered neuraminidase(s) expression levels in HexA−/−, HexA−/−Neu4−/
−, HexA−/−Neu4−/−Neu1−/−mice
Expression analysis of four mammalian neuraminidases (Neu1,
Neu2, Neu3 and Neu4) and HexB enzyme, isomer of HexA, in the brain
of the deficient mice revealed that deficiency of any neuraminidaseFig. 6.Accumulation of GM2 ganglioside in 3month oldHexA (B) HexA+Neu4 (D) and HexA+
GM2 accumulation neither in cortex (indicated by yellow C) nor in hippocampus (yellow H) reg
program (ImageJ) (n = 3, **p b 0.01).in the mouse brain triggers the expression of other neuraminidase(s).
HexB expression level decreased when the HexA gene is defective
in the 3 month old mice brain, but significantly increased in the
3 month old Neu4−/− mice and 6 month old HexA−/−Neu4−/−
mice (Fig. 9A). The neuraminidase-1 expression in the 3 month old
(HexA−/−, Neu4−/−, HexA−/−Neu4−/−, HexA−/−Neu1−/− and
HexA−/−Neu4−/−Neu1−/−) mice were higher than control, whereas
slightly increased expression level was detected in 6 month old mice
HexA−/−Neu4−/−Neu1−/− (Fig. 9B). In HexA−/−Neu4−/−Neu1−/−Neu4+Neu1 (E) deficientmice brain.Wild type (A) and Neu4 deficient (C) do not show
ion of brain. (F) Semiquantitative analysis of GM2 positive cells by US NIH image software
Fig. 7.Accumulation of GM2 ganglioside in 6month oldHexA (B) HexA+Neu4 (D) and HexA+Neu4+Neu1 (E) deficientmice brain.Wild type (A) and Neu4 deficient (C) do not show
GM2 accumulation neither in cortex (indicated by yellow C) nor in hippocampus (yellow H) region of brain. (F) Semiquantitative analysis of GM2 positive cells by US NIH image software
program (ImageJ) (n = 3, **p b 0.01).
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protective protein Cathepsin A (PPCA) coding gene expression was
interrupted by inserting neomycin cassette inserted in its non-coding
region. Neomycin insertion caused a decrease in the PPCA mRNA level
consistent with the reported hypomorphic (partial loss of function)
effects of the neomycin gene. Neuraminidase-1 makes a complex with
β-galactosidase and PPCA in lysosomes, therefore the decrease of
the PPCA gene expression does not cause changes in expressionFig. 8.Accumulation of GM2 ganglioside in 9month oldHexA (B) HexA+Neu4 (D) and HexA+
GM2 accumulation neither in cortex (indicated by yellow C) nor in hippocampus (yellow H) reg
program (ImageJ) (n = 3, **p b 0.01).level of neuraminidase-1 directly but results in high reduction of
neuraminidase-1 activity [17].
Expression of neuraminidase-2 is increased in both 3 and
6 month old mice in all genotypes. Expression level was significantly
higher especially in 6 month old HexA−/−Neu4−/−Neu1−/−mice as
compared to that of 3month oldmice (Fig. 9C). Neuraminidase-3 expres-
sion showed higher level in 3 month old HexA−/−, Neu4−/− and
HexA−/−Neu1−/− mice as compared to HexA−/−Neu4−/− andNeu4+Neu1 (E) deficientmice brain.Wild type (A) and Neu4 deficient (C) do not show
ion of brain. (F) Semiquantitative analysis of GM2 positive cells by US NIH image software
Fig. 9. Relative expressions of HexB (A) and Neu1 (B), Neu2 (C), Neu3 (D), Neu4 (E) sialidases in 3 and 6 month old HexA + Neu4 + Neu1 mice with wild type, single HexA and Neu4
deficient and double HexA + Neu4 deficient mice brains (n = 3, *p b 0.05, **p b 0,01).
Fig. 10. Specific enzyme activities of sialidase (A), β-glycosidase (B), β-galactosidase (C),α-L-iduronidase (D) in 6month old HexA+Neu4+Neu1micewithwild type, single HexA and
Neu4 deficient and double HexA + Neu4 deficient mice brains (n = 3, ns = not significant, *p b 0.05, **p b 0,01).
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ence in level of neuraminidase-3 expression between 3 month old
HexA−/−Neu4−/− and HexA−/−Neu4−/−Neu1−/−micewasdetect-
ed however in the 6 month old mice there was a lower level of
neuraminidase-3 expression in HexA−/−Neu4−/−Neu1−/− mice.
Neuraminidase-4 expression was only studied in HexA−/− and
HexA−/−Neu1−/− since Neu4 gene is deleted in Neu4−/−,
HexA−/−Neu4−/− and HexA−/−Neu4−/−Neu1−/− mice. Lower
expression of neuraminidase-4 was detected in both age groups
in HexA−/− and HexA−/−Neu1−/− mice brain (Fig. 9E).
3.6. Altered specific activity of neuraminidase-1, β-glucosidase, β-
galactosidase and α-L-iduronidase in deficient mice
Neuraminidase activity against artificial substrate 4-MU-N-
acetilneuraminic acid was measured to determine whether the in-
creased level of neuraminidase-2 and neuraminidase-3 expression re-
sults in an increase in the specific activity at protein level. No
differences were detected for neuraminidase activity in HexA−/− and
Neu4−/−mice compared toWT. However, 1.5 fold increased neuramin-
idase activity was detected in HexA−/−Neu4−/−Neu1−/− mice (Fig.
10A). This increase might be related to the increased expression level
of neuraminidase 2 and neuraminidase-3. In order to determinewheth-
er other independent lysosomal degradation pathways were affected
from deficiencies of HexA, neuraminidase-4 or neuraminidase-1
enzymes; β-glucosidase, β-galactosidase and α-L-iduronidase enzyme
activities were also measured. β-Glycosidase enzyme showed an
increased activity especially in HexA−/−Neu4−/−Neu1−/− mice
(Fig. 10B). In HexA−/−Neu4−/−Neu1−/− mice although there is an
increase in the activity of β-galactosidase enzyme compared to
HexA−/−Neu4−/−, the activity is not significantly different from WT
(Fig. 10C). α-L-iduronidase enzyme activity was also increased signifi-
cantly in the HexA−/−Neu4−/−Neu1−/− mice compared to WT and
remained unchanged in other mice (Fig. 10D). Relatively low changes
in the activities of these enzymesmight be the result of secondary accu-
mulated substrates of each enzyme in lysosomes.
4. Discussion
Tay–Sachs disease is the second most common lysosomal storage dis-
order in which GM2 ganglioside accumulates in the nerve cells due to the
deficiency of lysosomal β-Hexosaminidase A (HexA) enzyme. Accumula-
tion leads epileptic crisis, blindness, dementia, paralysis and even death in
the early ages. It has been reported that the disruption of the HEX A gene
inmouse embryonic stemcells resulted in amicemodel that have noneu-
rologic abnormalities up to one year of age [5]. The phenotypic differences
between Tay–Sachs mouse model and Tay–Sachs patients suggested that
the ganglioside degradation pathways inhumans andmice are different. It
was hypothesized thatmouse neurons are enriched in a lysosomal gangli-
oside neuraminidase activity which removes the terminal sialic acid from
GM2 ganglioside converting it into glycolipid GA2 which is further
degraded by enzyme β-Hexosaminidase B [7]. The involvement of
neuraminidase-4 in metabolic bypass was previously studied in mouse
showing some (with epileptic crisis) but not all HexA−/−Neu4−/−mice
have the increased accumulation of GM2 ganglioside in the brain cortex.
Since 40% of HexA−/−Neu4−/−mice showed Tay–Sachs related features,
we suggested that neuraminidase-4 is not only neuraminidase in
metabolic bypass but may be other neuraminidase(s) also have role in
this pathway along with neuraminidase-4 [9]. In the current work, we
assessed whether lysosomal neuraminidase-1, with neuraminidase-4, is
responsible in vivo for the metabolic bypass in the HexA deficient
mouse model of Tay–Sachs disease by studying a mice model with the
deficiencies of β-hexosaminidase A, neuraminidase-4 and reduced
neuraminidase-1 (10% of normal activity).
Neuraminidase Neu1 had a strong GM3 and GD1a ganglioside hydro-
lyzing activity, but weak activity toward GM2 ganglioside, in vitro.Besides, the impairedmetabolism of GM3 ganglioside in cultured skin fi-
broblasts from sialidosis and galactosialidosis patients was reported
with a storage of GM3 and GD3 gangliosides in visceral tissues but not
in brain of sialidosis patients [17]. Ganglioside profiling with both thin
layer chromatography and mass spectrometry analysis revealed that
HexA−/−Neu4−/−Neu1−/− mice had an altered ganglioside pattern,
different from HexA−/−Neu4−/− mice, compatible with the previous
studies that show neuraminidase-1 function on gangliosides. Although
HexA−/−Neu4−/− mice had an increased GM2 and a decreased GM1
ganglioside level, HexA−/−Neu4−/−Neu1−/− mice had increased
level of GM3, GD1, GD2, GD3 and GT1 gangliosides with SM4 sulfatides
which are themembers of b series gangliosides [18]. Since the deficien-
cy of neuraminidase-1 resulted in increased level of these b-series gan-
gliosides, but not GM2 ganglioside, we suggest that neuraminidase-1
contributes the degradation of b-series gangliosides but not the
metabolic bypass in HexA−/− mice. Since HexA−/−Neu1−/−
and HexA−/−Neu4−/−Neu1−/− mice have 10% of normal activity
neuraminidase-1, we speculate that the level of enzyme activity might be
enough to degrade GM2 ganglioside in mice causing no excessive accumu-
lation. To reveal the exact effect of neuraminidase-1 on ganglioside
degradation in vivo, a previously generated knockout mouse model of
neuraminidaseNeu1might beused to obtainHexA−/−Neu1−/−mice [16].
Studies of brain tissue fromTay–Sachsdisease showed that one third
of the dry weight to be ganglioside, mostly GM2 but there are also de-
tectable amounts of asialo-GM2, LacCer, and glucocerebrosides [19]. In
our study we showed that Cer, CerP, GalCer and LacCer amounts are
higher in HexA−/−Neu4−/− as well as HexA−/−Neu4−/−Neu1−/−
mice brain compared to HexA−/− mice although it was relatively
lower than that of WT mice. These results showed that deficiency of
neuraminidase-1 and neuraminidase-4 causes the accumulation of
Cer, CerP, LacCer and GalCer compared to HexA−/−mice. Myelin covers
and facilitates the propagation of an electrical impulse down the axon to
transmit information from one neuron to another. In many lysosomal
storage disorder the myelin sheath deformation was reported [20].
GalCer, sulfatide, and sphingomyelin are structural components of my-
elin sheaths and major lipids in oligodendrocytes and Schwann cells in
the brain [21]. Additionally, analysis of Tay–Sachs disease patient sam-
ples revealed accumulation of not only GM2 ganglioside but also sec-
ondary lipids for example phospholipids, cerebrosides, sphingomyelin,
cholesterol and cholesterol esters, and so forth [19]. In our study,
the accumulation of phosphatidylcholine and sphingomyelin in
HexA−/−Neu4−/− and HexA−/−Neu4−/−Neu1−/− was shown for
the first time by mass spectrometry. The accumulation of phosphati-
dylcholine and sphingomyelin, was higher in the brain from
HexA−/−Neu4−/− than HexA−/−Neu4−/−Neu1−/−which indicates
the possible role of neuraminidase-1 as well as neuraminidase-4 in
the phosphatidylcholine and sphingomyelin metabolism.
Real-time PCR analysis for neuraminidases showed that
neuraminidase-2 and neuraminidase-3 had an increased gene ex-
pression in all deficient mice (Fig. 9). The increased expression
level of neuraminidase-2 and neuraminidase-3 in HexA−/−Neu4−/−
mice was found as previously shown [9], while expression level in
HexA−/−Neu4−/−Neu1−/− mice was shown for the first time in
this study. Although neuraminidase-3 is the most active neuramini-
dase on gangliosides [8] there was not a significant difference in
neuraminidase enzyme activity in both HexA−/−Neu4−/− and
HexA−/−Neu4−/−Neu1−/− mice (Fig. 10). Also there is an increase
in the expression level of neuraminidase-1whichmay result from the ac-
cumulated substrates in the lysosome because of insufficient activity of
neuraminidase-1. The cell may need more neuraminidase-1 activity and
express neuraminidase-1 more than normal conditions but since there
is not enough PPCA protein in the lysosome neuraminidase-1 cannot
form an active complex and cannot degrade all substrates. When we
combine the gene expression resultswith neuraminidase enzyme activity
results, we speculate that this unchanged neuraminidase activity in
HexA−/−Neu4−/− and HexA−/−Neu4−/−Neu1−/− mice may occur
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neuraminidase-3 in these two mice models. So in the absence of
neuraminidase-4 and neuraminidase-1, neuraminidase-2 and/or
neuraminidase-3 might have an increased function in the ganglio-
side degradation pathway (especially for GM2 ganglioside degrada-
tion that cannot completely degrade as a result of HexA enzyme
deficiency) which causes GM2 ganglioside not to accumulate further
in the HexA−/−Neu4−/−Neu1−/− mice. Besides neuraminidase en-
zyme activity, we observed non-significant changes in other studied en-
zymes; β-glucosidase, β-galactosidase and α-L-iduronidase enzymes.
We didn't expect to see increased activity of β-galactosidase enzyme
in HexA−/−Neu4−/−Neu1−/− mice since PPCA gene is defected but
some studies showed thatβ-galactosidase has its own activity indepen-
dently from the lysosomal multienzyme complex [22]. So we speculate
that the lowexpression level of PPCA seems not to cause a complete loss
ofβ-galactosidase enzyme activity in thesemicemodels. The changes in
enzymes' activity might be the result of altered lysosomal conditions
because all degradation reactions take part in the lysosome. When
high levels of macromolecules accumulate in lysosomes such as gangli-
osides, they inhibit other catabolic enzymes that are not genetically de-
ficient due to secondary substrate accumulation [23]. These enzymes
are responsible for the degradation of glucocerebroside, GM1 gangli-
oside and keratan sulfate and glycosaminoglycans respectively, so
the increased activity of each enzyme might be the result of
undegraded substrates that might be accumulated by the secondary
effect of neuraminidase-1 deficiency. Detailed analysis for
glucocerebroside, keratan sulfate and glycosaminoglycan accumula-
tion in HexA−/−Neu1−/− and HexA−/−Neu4−/−Neu1−/− mice
helps us to better understand the function of neuraminidase-1 on
substrate degradation with or without neuraminidase-4.
In this study we showed that although both neuraminidase-1 and
neuraminidase-4 have function on ganglioside degradation in vivo,
they differ in their ganglioside specificity. It was previously shown
that in addition to lysosomal catabolism, neuraminidase-1 regulates
various important cellular events through desialylation of surfacemole-
cules, like activating the phagocytosis in macrophages and dendritic
cells [17], activating macrophages and forming a link to the cellular im-
mune response [24], regulating insulin signaling [25] and regulating ly-
sosomal exocytosis [26]. It was shown inmany studies that gangliosides
in the cell membrane function in cell to cell recognition, adhesion and
especially in signal transduction [12,21]. For instance, GD1 and GT1 gan-
gliosides have functions in receptor tyrosine kinase activation, GD2 gan-
glioside involves in the activation of c-Met through MEK/Erk and PI3K/
Akt signaling pathways and enhances cell migration and proliferation,
GM3 ganglioside interacts with EGFR, FGFR and VEGFR and inhibits
their kinase activities and also importantly GM3 ganglioside negatively
regulates insulin receptor and causes partial insulin resistance [27].
Sulfatides (SM4s) are sulfoglycolipid that have specific functions in
both the central nervous system and visceral organs [28] such as li-
gand binding to cell membrane [29] and their expressions are altered
in many cancer types [30,31]. Like other lysosomal storage diseases,
Tay–Sachs display similar cellular pathological phenotypes that re-
sulted from altered cellular processes such as reduction in autopha-
gy, changes in calcium homeostasis, ER defects, mitochondrial
dysfunctions and inhibited lipid trafficking [23]. Since specific gan-
gliosides and sulfatides are accumulated in newly generated
HexA−/−Neu4−/−Neu1−/− and HexA−/−Neu1−/−mice, these models
can be studied further to reveal how abovementioned cellular pathways
are affected by neuraminidase-1 deficiency, b-series gangliosides and/
or sulfatide alteration with or without neuraminidase-4.
5. Conclusion
With the analysis of HexA−/−Neu4−/−Neu1−/−mice, we conclude
that neuraminidase-1 contributes to the degradation of b-series gan-
gliosides but not the metabolic bypass in HexA−/− mice. Since,HexA−/−Neu1−/− and HexA−/−Neu4−/−Neu1−/− mice have 10%
of normal activity neuraminidase-1, we speculate that the level
might be still high enough to degrade GM2 ganglioside in mice causing
no accumulation. To reveal the exact effect of neuraminidase-1 on gan-
glioside degradation in vivo, a previously generated knockout mouse
model of neuraminidase-1 can be used to obtain HexA−/−Neu1−/−
mice [16]. Our study indicates that not only neuraminidase-4
and neuraminidase-1 but also other neuraminidases such as
neuraminidase-2 and/or neuraminidase-3 may be involved in ganglio-
side degradation pathway in mouse. Therefore, new mouse models
with combined deficiency of Hexosaminidase A and neuraminidase
Neu2/Neu3 can be used to enlighten the roles of neuraminidase(s) in
mice ganglioside degradation pathway which is different from human.
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